Treatment of Steroid-Resistant Acute Renal Allograft Rejection With Alemtuzumab

van den Hoogen, 2012, Anti-T cell antibodies for the treatment of acute rejection after renal transplantation, Expert Opin Biol Ther, 12, 1031, 10.1517/14712598.2012.689278 Webster, 2006, Monoclonal and polyclonal antibody therapy for treating acute rejection in kidney transplant recipients: A systematic review of randomized trial data, Transplantation, 81, 953, 10.1097/01.tp.0000215178.72344.9d Uslu, 2011, Treatment of first acute rejection episode: Systematic review of level I evidence, Transplant Proc, 43, 841, 10.1016/j.transproceed.2010.11.018 Hardinger, 2006, Rabbit antithymocyte globulin induction therapy in adult renal transplantation, Pharmacotherapy, 26, 1771, 10.1592/phco.26.12.1771 Frampton, 2003, Alemtuzumab, Drugs, 63, 1229, 10.2165/00003495-200363120-00003 Thomas, 2004, Campath and renal transplant rejection, ClinTransplant, 18, 759 Csapo, 2005, Campath-1H as rescue therapy for the treatment of acute rejection in kidney transplant patients, Transplant Proc, 37, 2032, 10.1016/j.transproceed.2005.03.042 Upadhyay, 2012, Safety and efficacy of alemtuzumab in the treatment of late acute renal allograft rejection, Pediatr Transplant, 16, 286, 10.1111/j.1399-3046.2011.01615.x Basu, 2005, Reversal of acute cellular rejection after renal transplantation with Campath-1H, Transplant Proc, 37, 923, 10.1016/j.transproceed.2004.12.019 Clatworthy, 2009, Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: Long-term follow-up, Transplantation, 87, 1092, 10.1097/TP.0b013e31819d3353 Hanaway, 2011, Alemtuzumab induction in renal transplantation, N Engl J Med, 364, 1909, 10.1056/NEJMoa1009546 Rai, 2002, Future prospects for alemtuzumab (MabCampath), Med Oncol, 19, S57, 10.1385/MO:19:2S:S57 Racusen, 1999, The Banff 97 working classification of renal allograft pathology, Kidney Int, 55, 713, 10.1046/j.1523-1755.1999.00299.x Bloom, 2006, T-lymphocyte alloresponses of Campath-1H-treated kidney transplant patients, Transplantation, 81, 81, 10.1097/01.tp.0000191940.13473.59 Margreiter, 2008, Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: Results of a prospective randomized trial, Am J Transplant, 8, 1480, 10.1111/j.1600-6143.2008.02273.x Peleg, 2007, Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody, Clin Infect Dis, 44, 204, 10.1086/510388